These PAM50 subtypes, which are still an important basis for clinical decisions today, include the two estrogen receptor-dependent subtypes, luminal A (LumA) and luminal B (LumB), the Human epidermal growth factor receptor 2 (HER2)-positive subtype and basal-like (basal) breast cancer. Here, ERBB2 is linked to breast carcinoma.